Apyx Medical Corp. (APYX) Tops Q4 EPS by 3c, Revenues beat; Offers Q1 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Apyx Medical Corp. (APYX) Tops Q4 EPS by 3c, Revenues beat; Offers Q1 Revenue Guidance Below Consensus

Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook

March 16, 2020 4:05 PM EDT

Advanced Energy Sales increase 58% year-over-year in Q4 and increase 73% year-over-year in FY'19

CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary unaudited financial results for its fourth quarter and fiscal year ended December 31, 2019 and introduced financial expectations for the first quarter ending March 31, 2020.

The financial information contained herein are... More